Abstract:Background. The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-year overall survival rate is just 63% even for the pathological IA stage. Thus, in order to identify high-risk patients and facilitate clinical decision making, it is vital that we identify new prognostic markers that can be used alongside TNM staging to facilitate risk stratification. Methods. We used mRNA expression from The Cancer Genome Atlas (TCGA) cohort to identify a prognostic gene signature and combined this with clinical data to develop a predictive model for the prognosis of patients for lung adenocarcinoma. Kaplan-Meier curves, Lasso regression, and Cox regression, were used to identify specific prognostic genes. The model was assessed via the area under the receiver operating characteristic curve (AUC-ROC) and validated in an independent dataset (GSE50081) from the Gene Expression Omnibus (GEO). Results. Our analyses identified a four-gene prognostic signature (CENPH, MYLIP, PITX3, and TRAF3IP3) that was associated with the overall survival of patients with T1-4N0-2M0 in the TCGA dataset. Multivariate regression suggested that the total risk score for the four genes represented an independent prognostic factor for the TCGA and GEO cohorts; the hazard ratio (HR) (high risk group vs low risk group) were 2.34 (p < 0.001) and 2.10 (p = 0.017). Immune infiltration estimations, as determined by an online tool (TIMER2.0) showed that CD4+ T cells were in relative abundance in the high risk group compared to the low risk group in both of the two cohorts (both p < 0.001). We established a composite prognostic model for predicting OS, combined with risk-grouping and clinical factors. The AUCs for 1-, 3-, 5- year OS in the training set were 0.750, 0.737, and 0.719; and were 0.645, 0.766, and 0.725 in the validation set. The calibration curves showed a good match between the predicted probabilities and the actual probabilities. Conclusions. We identified a four-gene predictive signature which represents an independent prognostic factor and can be used to identify high-risk patients from different TNM stages of LUAD. A new prognostic model that combines a prognostic gene signature with clinical features exhibited better discriminatory ability for OS than traditional TNM staging.

5-Mrna-based Prognostic Signature of Survival in Lung Adenocarcinoma

LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma

Development And Validation Of A Seven-Gene Signature For Predicting The Prognosis Of Lung Adenocarcinoma

Identification of Key Genes in Lung Adenocarcinoma and Establishment of Prognostic Mode

A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Large-scale Gene Expression Analysis Reveals Robust Gene Signatures for Prognosis Prediction in Lung Adenocarcinoma

Integrated Bioinformatics Analysis Identifies a New Stemness Index-Related Survival Model for Prognostic Prediction in Lung Adenocarcinoma

A Prognostic Signature Model for Unveiling Tumor Progression in Lung Adenocarcinoma

A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma

A Five Autophagy-Related Long Non-Coding RNA Prognostic Model for Patients with Lung Adenocarcinoma

A Model of Twenty-Three Metabolic-Related Genes Predicting Overall Survival for Lung Adenocarcinoma

Combining Genetic Mutation and Expression Profiles Identifies Novel Prognostic Biomarkers of Lung Adenocarcinoma.

An eleven-gene risk model associated with lymph node metastasis predicts overall survival in lung adenocarcinoma

A Robust Gene Expression-Based Prognostic Risk Score Predicts Overall Survival of Lung Adenocarcinoma Patients.

Identification of an eight-gene prognostic signature for lung adenocarcinoma.

Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations

A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients with Lung Adenocarcinoma

Predicting the survival of patients with lung adenocarcinoma using a four-gene prognosis risk model

A Novel Mitochondrial-Related Gene Signature for the Tumor Immune Microenvironment Evaluation and Prognosis Prediction in Lung Adenocarcinoma